Luron Fleming
Psychiatric/Mental Health · Greenville, SCNPI 1376172502
Payments from drug & device makers
Across 669 payments — averaging $91.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$48K
- AbbVie$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Supernus Pharmaceuticals, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$717
- plus $5K from 27 others
What the payments were for
- Consulting fees$15,37525%
- Speaking & faculty fees$22,12536%
- Travel & lodging$9,13715%
- Food & beverage$14,52824%
- Education$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 109 | $47,555 |
| AbbVie | 158 | $4,498 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $1,402 |
| Otsuka America Pharmaceutical, Inc. | 64 | $1,317 |
| Supernus Pharmaceuticals, Inc. | 16 | $1,037 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $717 |
| Sunovion Pharmaceuticals Inc. | 30 | $600 |
| Johnson & Johnson | 26 | $543 |
| Alkermes, Inc. | 20 | $498 |
| Vanda Pharmaceuticals Inc. | 25 | $485 |
| Neurocrine Biosciences, Inc. | 19 | $438 |
| E.r. Squibb & Sons, L.L.C. | 8 | $335 |
| Lundbeck LLC | 17 | $304 |
| Bausch Health US, LLC | 16 | $271 |
| Avanir Pharmaceuticals, Inc. | 10 | $155 |
| Teva Pharmaceuticals USA, Inc. | 10 | $152 |
| Ironshore Pharmaceuticals Inc. | 5 | $136 |
| Biogen | 3 | $125 |
| Acadia Pharmaceuticals Inc | 5 | $111 |
| Tris Pharma Inc | 6 | $108 |
| Almatica Pharma LLC | 6 | $95 |
| Corium, LLC | 4 | $70 |
| Merck | 4 | $59 |
| Idorsia Pharmaceuticals US Inc | 4 | $55 |
| Gilead | 3 | $46 |
| Noven Therapeutics, LLC | 2 | $42 |
| TMS Neurohealth Centers Inc. | 1 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Eisai Inc. | 2 | $29 |
| Sage Therapeutics, LLC | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,325 in reported general payments places this provider in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LybalviOlanzapine/Samidorphan Malate | 15 | $23,660 |
| CaplytaLumateperone Tosylate | 12 | $23,094 |
| AuvelityDextromethorphan Hbr/Bupropion | 24 | $20,104 |
| RexultiBrexpiprazole | 12 | $16,603 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,637 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 18 | $5,337 |
| Quetiapine Fumarate | 105 | $2,070 |
| Atomoxetine Hcl | 11 | $1,462 |
| Fluoxetine Hcl | 53 | $1,151 |
| Paliperidone ErPaliperidone | 12 | $1,069 |
| Bupropion XlBupropion Hcl | 79 | $1,026 |
| Aripiprazole | 28 | $990 |
| Hydroxyzine Hcl | 46 | $939 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 32 | $908 |
| Ziprasidone Hcl | 28 | $785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi | $498 | $23,66015 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,402 | $23,09412 claims |
| Axsome Therapeutics, Inc.Auvelity | $47,555 | $20,10424 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,317 | $16,60312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $717 | $6,63716 claims |
| Almatica Pharma LLCSertraline Hcl | $95 | $6822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Greenville
- Steven KrozerGreenville$139K
- Lauren DyerGreenville$16K
- Melissa BrownGreenville$16K
- William HendricksGreenville$13K
- Carrie BallengerGreenville$11K
- Gregory SmithGreenville$9K
- Svetlana RobinsonGreenville$8K
- Jared CarboneGreenville$7K
- Anglique RichGreenville$6K
- Matthew HendricksGreenville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.